Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 1, 2003, Pages 403-408

  Berglin, Lennart ^a   Sarman, Sylvia ^a   Van der Ploeg, Ingeborg ^a   Steen, Björn ^a   Ming, Yue ^a   Itohara, Shigeyoshi ^b   Seregard, Stefan ^a   Kvanta, Anders ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^c ST ERIK S EYE HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; EOSIN; GELATINASE A; HEMATOXYLIN; MESSENGER RNA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME DEFICIENCY; FEMALE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; KRYPTON LASER; LASER COAGULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETINA MACULA AGE RELATED DEGENERATION; RNA PROBE; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FEMALE; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; LASER COAGULATION; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RNA PROBES; RNA, MESSENGER; UP-REGULATION;

EID: 0037253085     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0180     Document Type: Article

References (31)

1. Evans JR. Causes of Blindness and Partial Sight in England and Wales 1990-1991: Studies on Medical and Population Subjects 57. London: HSMO; 1995:22-33.
2. Berglin L, Algvere PV, Olivestedt G, et al. The Swedish national survey of surgical excision for submacular choroidal neovascularization (CNV). Acta Ophthalmol Scand. 2001;79:580-584.
3. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-248.
4. Sethi CS, Bailey TA, Luthert PJ, Chong NHV. Matrix metalloproteinase biology applied to vitreoretinal disorders. Br J Ophthalmol. 2000;84:654-666.
5. Stamencovic I. Matrix metalloproteinases in tumor Invasion and metastasis. Semin Cancer Biol. 2000;10:415-433.
6. Ravanti L, Kahari VM. Matrix metalloproteinases in wound repair (review). Int J Mol Med. 2000;6:391-407.
7. Zhou Z, Apte SS, Soninen R, R Cao, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA. 2000;97:4052-4057.
8. Soini Y, Hurskainen T, Hoyhtya M, Oikarinen A, Autio-Harmainen H. 72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. J Histochem Cytochem. 1994;42:945-951.
9. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998;58:1048-1051.
10. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737-744.
11. Steén B, Sejersen S, Berglin L, Seregard S, Kvanta A. Matrix metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1998;39:1994-2000.
12. Kvanta A, Shen WY, Sarman S, Seregard S, Stéen B, Rakoczy E. Matrix metalloproteinase (MMP) expression in experimental choroidal neovascularization. Curr Eye Res. 2000;21:684-690.
13. Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S. Unaltered secretion of β-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem. 1997;272:22389-22392.
14. Tobe T, Ortega S, Luna JD, et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol. 1998;153:1641-1646.
15. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:3158-3164.
16. Okada A, Tomasetto C, Lutz Y, Bellocq JP, Rio MC, Basset P. Expression of metalloproteinases during ratskin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A. J Cell Biol. 1997;137:67-77.
17. Dew G, Murphy G, Stanton H, et al. Localisation of matrix metalloproteinases and TIMP-2 in resorbing mouse bone. Cell Tissue Res. 2000;299:385-394.
18. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929-1934.
19. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised agerelated macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
20. Ishibashi T, Hata Y, Yoshikawwa H, Nakagawa K, Sueishi K, Inomata H. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1997;235:159-167.
21. Hangai M, Moon YS, Kitaya N, et al. Systemically expressed soluble Tie2 inhibits intraocular neovascularization. Hum Gene Ther. 2001;12:1311-1321.
22. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 1977;14:53-65.
23. Zhang NL, Samadani EE, Frank RN. Mitogenesis and retinal pigment epithelial cell antigen expression in the rat after krypton laser photocoagulation. Invest Ophthalmol Vis Sci. 1993;34:24122424.
24. Kato T, Kure K, Chang J-H, et al. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett. 2001;508:187-190.
25. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 1998;92:391-400.
26. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol. 2001;21:1104-1117.
27. Noel A, Bajou K, Masson V, et al. Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1. Fibrinolysis Proteolysis. 1999;13:220-225.
28. Lambert V, Munaut C, Noël A, et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J. 2001;15:1021-1027.
29. Rivero ME, Garcia CR, Hagedom M, et al. Intraocular properties of AG 3340, a selective matrix metalloproteinases inhibitor with antiangiogenic activity [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1998;39(4):S585. Abstract nr 2707.
30. El-Bradey MH, Cheng L, Appelt K, et al. Prevention of experimental laser induced choroidal neovascularization by intravitreal injection of AG3340 [ARVO Abstract]. Invest Ophthalmol Vis Sci. 2001;42(4)S521. Abstract nr 2805.
31. Blodi BA. Effects of prinomastat (AG 3340), an angiogenesis inhibitor, in patients with subfoveal choroidal neovascularization associated with age-related macular degeneration [ARVO Abstract]. Invest Ophthalmol Vis Sci. 2001;42(4)S311. Abstract nr 1673.